The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

TLR9 agonists are being developed for treatment of colorectal and other cancers, yet the impact of these drugs on human intestines remains unknown. This, together with the fact that there are additional potential indications for TLR9 agonist therapy (e.g. autoimmune and infectious diseases), led us...

Descripción completa

Detalles Bibliográficos
Autores principales: Krarup, Astrid Raaby, Abdel-Mohsen, Mohamed, Schleimann, Mariane H., Vibholm, Line, Engen, Phillip A., Dige, Anders, Wittig, Burghardt, Schmidt, Manuel, Green, Stefan J., Naqib, Ankur, Keshavarzian, Ali, Deng, Xutao, Olesen, Rikke, Petersen, Andreas Munk, Benfield, Thomas, Østergaard, Lars, Rasmussen, Thomas A, Agnholt, Jørgen, Nyengaard, Jens Randel, Landay, Alan, Søgaard, Ole S., Pillai, Satish K., Tolstrup, Martin, Denton, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796873/
https://www.ncbi.nlm.nih.gov/pubmed/28766555
http://dx.doi.org/10.1038/mi.2017.59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796873/
https://www.ncbi.nlm.nih.gov/pubmed/28766555
http://dx.doi.org/10.1038/mi.2017.59

Ejemplares similares